
Former KL2 Scholar Named to TIME100 Health List
Summary
Emil Lou, M.D., Ph.D., has been named to the 2026 TIME100 Health List, which recognized his innovative approach to translational research in oncology. Dr. Lou, a professor with the University of Minnesota, led a first-in-human clinical trial that used CRISPR/Cas9 gene editing to help the immune system target advanced gastrointestinal cancers. Dr. Lou has longstanding ties to the Clinical and Translational Science Institute at the University of Minnesota, where he received early-career support for his research through the KL2 Scholars Career Development Program.
Article
Emil Lou, M.D., Ph.D., has been named to the 2026 TIME100 Health List of the world’s most influential health leaders, an honor that recognizes individuals driving major advances in medicine and science. He has longstanding ties to the Clinical and Translational Science Institute (CTSI) at the University of Minnesota through both its scholar and mentoring programs.
Dr. Lou began his CTSI involvement as an awardee in the KL2 Scholars Career Development Program, where he received early career support for his research. He has since remained engaged with CTSI by serving as a mentor to trainees in the TL1 program (now known as the T32 Program) and the Translational Research Development Program, helping support the development of future translational researchers.
Celebrated nationally for advancing cancer research
The TIME100 Health List recognized Dr. Lou for his innovative approach to translational research in oncology. He led a first-in-human clinical trial that used CRISPR/Cas9 gene editing to help the immune system target advanced gastrointestinal cancers.
Published in The Lancet Oncology, the study points to a promising new direction for patients with late-stage disease. It also underscores the importance of translational science that bridges laboratory discovery and clinical care.
https://ctsi.umn.edu/news/dr-emil-lou-named-2026-time100-health-list-worlds-most-influential-health-leaders




